Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

16-06-2017 | Psoriatic arthritis | EULAR 2017 | Video

EULAR 2017 highlights: Philip Mease

This activity is financially supported by Novartis Pharma AG

Related content

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial

20-08-2018 | Psoriatic arthritis | Feature | Article

Into the clinic: Ixekizumab for the treatment of PsA

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

06-04-2018 | Spondyloarthropathies | Feature | Article

At a glance: Trials of tofacitinib in spondyloarthritis
Image Credits